CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development.
Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards.
CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected.
We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population.
CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category.
CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $120M
Founded date: 2008
Investors 3
Date | Name | Website |
- | Tech Coast... | techcoasta... |
- | ATEL Capit... | atel.com |
- | Canaan Par... | canaan.com |
Funding Rounds 3
Date | Series | Amount | Investors |
17.06.2015 | Series D | $70M | - |
06.01.2015 | Series C | $20M | - |
23.09.2010 | Series B | $30M | - |
Mentions in press and media 22
Date | Title | Description | Source |
11.03.2024 | CytomX Therapeutics Reports 2023 Financial Results and Provi... | - | globenewsw... |
05.01.2023 | Moderna and CytomX Announce Strategic Research Collaboration... | Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and... | accesswire... |
04.11.2021 | CytomX Therapeutics Announces Third Quarter 2021 Financial R... | CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update -Ini... | marketscre... |
05.08.2021 | CytomX Therapeutics Announces Second Quarter 2021 Financial ... | SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CT... | marketscre... |
06.05.2021 | CYTOMX THERAPEUTICS, INC. CytomX Therapeutics Announces Fir... | SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTM... | marketscre... |
23.09.2020 | Endpoints News: A longtime CytomX exec re-emerges at Synthek... | - | canaan.com... |
20.03.2017 | BMS signs new $200M licensing deal for CytomX probodies | It builds on a similar agreement announced in 2014, which saw BMS license up to four candidates for ... | medcitynew... |
20.03.2017 | A small drug company that's trying to make cancer treatments... | REUTERS/Suzanne Plunkett A tray containing cancer cells sits on an optical microscope in the Nanomed... | businessin... |
29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
17.06.2015 | Immunotherapy startup CytomX raises $70M; IPO on horizon | The financing, which comes on the heels of a $20 million Series C led by Pfizer, targets PD-L1 and “... | medcitynew... |
Show more